Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27530022 | 0.92 | CA1 (0.43) | CA1CA2CA4GLB1EPHX1 | |
| SCHEMBL11506851 | 0.85 | PABPC1 (0.34) | CA1CA2CA4TDP1 | |
| SCHEMBL3480002 | 0.85 | CA1 (0.50) | CA1CA2CA4GLB1 | |
| SCHEMBL11514009 | 0.85 | PABPC1 (0.34) | CA1CA2CA4TDP1 | |
| SCHEMBL11506853 | 0.85 | PABPC1 (0.34) | CA1CA2CA4TDP1 | |
| SCHEMBL28135069 | 0.75 | — | — | |
| SCHEMBL10060033 | 0.74 | — | — | |
| SCHEMBL12765188 | 0.74 | — | — | |
| SCHEMBL16705637 | 0.74 | — | — | |
| SCHEMBL12508092 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2018-08-30 | — | — | US | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160304478-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304478-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-9428452-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-08-30 | — | — | US | disclosed |
| US-9428452-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-08-30 | — | — | US | disclosed |
| CN-104718188-A | N-substituted benzamides and their use in the treatment of pain | GENENTECH INC | 2015-06-17 | — | — | CN | disclosed |
| EP-2855428-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | Genentech, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-1158982-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6376496-B1 | TREATMENT OF CANCER | MERCK & CO., INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1158982-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| CN-1298400-A | Novel cyclic pro-perfumes capable of releasing perfume raw material alcohols at variable rates | PROCTER & GAMBLE (US) | 2001-06-06 | — | — | CN | disclosed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000052134-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0128654-B1 | GEM-DIAMINOALKANE DERIVED SWEETENERS | CUMBERLAND PACKING CORPORATION (US) | 1989-10-18 | — | — | EP | disclosed |
| EP-0242896-A2 | Novel intermediates useful in the production of gem-diaminoalkane derived sweeteners | CUMBERLAND PACKING CORPORATION (US) | 1987-10-28 | — | — | EP | disclosed |
| US-4571345-A | 1,1-Diaminoalkane derived sweeteners | CUMBERLAND PACKING CORP. (US) | 1986-02-18 | — | — | US | disclosed |
| EP-0128654-A2 | Gem-diaminoalkane derived sweeteners | CUMBERLAND PACKING CORPORATION (US) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | CA1 2133/4885CA2 1240/4885CA4 2023/4885 |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | CA1 2133/4885CA2 1240/4885CA4 2023/4885 |
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | CA1 2456/4885CA2 1660/4885CA4 1497/4885 |
| US-20160304478-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | CA1 4007/4885CA2 3833/4885CA4 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.